Nyrada Inc. (ASX:NYR)

Walter Reed Army Institute of Research has listed Nyrada Inc. (ASX:NYR) as an Industry Partner in its Traumatic Brain Injury (TBI) program. TBI is a major threat to Soldier readiness and currently lacks any FDA-approved drug treatment options. Nyrada and WRAIR are working to fill this capability gap by developing novel, ground-breaking solutions to mitigate TBI at the point-of-injury to reduce morbidity and mortality. More information at https://bit.ly/40rS6p8 #TBI #BrainAwareness #BrainHealth James Bonnar John Moore

Please vote at Nyrada Inc. (ASX:NYR)'s coming Annual General Meeting. Nyrada will hold its Annual General Meeting on Tuesday, 12 November 2024. This will be an in-person only meeting in Sydney. CDI holders are encouraged to attend if you are able. Please register your interest at info@nyrada.com.   Date of meeting: Tuesday 12 November 2024 Time: 9.30am (AEDT) Location: Automic Group offices, Level 5, 126 Phillip Street, Sydney, NSW 2000   No matter whether you can attend, your vote is important for this meeting to proceed. To vote, please refer to the Notice of Meeting or go directly to the shareholder portal at https://lnkd.in/gC6N6f9J. Thank you for your support. John Moore James Bonnar  #AGM #biotech #Sydney #ASX

Nyrada Inc. (ASX:NYR) today announced the results of a successful capital raise. $3.36 million of new equity capital (before costs) was raised by way of a placement to institutional, sophisticated and professional investors. The placement follows recent successful completion of GLP studies for lead drug candidate NYR-BI03 with Phase I in-human clinical study expected to commence by end of CY2024. In addition to its preclinical neuroprotection efficacy, NYR-BI03 has demonstrated strong preclinical efficacy in limiting heart damage associated following ischemia-reperfusion injury, offering a significant additional market opportunity. Nyrada will also undertake a #SPP on the same terms as the Placement targeting an additional $1.00 million of new equity capital (before costs). Funds raised will be used primarily for completion of Phase Ia clinical trial and Investigational New Drug applications with the US FDA. More information available at https://bit.ly/3NG3Ts3 and https://bit.ly/4eYeXwZ. John Moore James Bonnar

Nyrada Inc. (ASX:NYR) released its Quarterly Activities Report & Appendix 4C this morning. More information here - https://bit.ly/3NCAyis. Highlights include: • Nyrada successfully completes Good Laboratory Practice safety studies of lead drug candidate NYR-BI03. • Preclinical efficacy study showed NYR-BI03 provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury. • Australian based Contract Research Organisation engaged to conduct first-in-human Phase I clinical trial for NYR-BI03 commencing in late 2024. • Cash position of AU$2.98 million as at 30 September 2024. AU$1.38 million R&D tax rebate expected in late 2QFY2025. James Bonnar John Moore

Nyrada Inc. (ASX:NYR) today announces the results from supplementary preclinical studies confirming its lead drug candidate, NYR-BI03 prevents loss of function resulting from myocardial ischemia-reperfusion (IR) injury following myocardial infarction (heart attack) in rats. Nyrada CEO James Bonnar commented: “The confirmation of significant cardioprotective effects from NYR-BI03 in preclinical studies represents another milestone for Nyrada. Heart attacks affect 15-20 million people globally each year, with up to 15% mortality within 30 days due to complications like heart failure. Additionally, up to 50% of heart tissue damage is caused by reperfusion injury, where restoring blood flow after a heart attack paradoxically causes further damage to the heart. “The substantial improvements in heart function and structure shown in these supplementary studies are particularly encouraging as there are currently no FDA-approved therapies targeting ischemia-reperfusion injury. “We are excited to advance NYR-BI03 into clinical trials and believe it has the potential to transform the standard of care for heart attack survivors." More information at https://bit.ly/48mrN5t John Moore

Nyrada Inc. (ASX:NYR) has today announced that it has successfully completed Good Laboratory Practice safety studies of lead drug candidate NYR-BI03 indicating that it is well tolerated with a favourable safety profile. Nyrada is moving forward with its Human Ethics Research Committee submission, subject to which, Nyrada will initiate its first-in-human Phase I clinical trial for NYR-BI03 in late 2024. The Phase I trial, to be conducted in Australia, will provide valuable data applicable to both neuroprotection and cardioprotection programs. The trial is expected to continue until the second half of calendar 2025. Further information at https://bit.ly/3BMFoXL John Moore James Bonnar

Yesterday, Nyrada Inc. (ASX:NYR) CEO James Bonnar spoke to Juliette Saly at ausbiz about the company’s recent progress advancing the development of its drug candidate, NYR-BI03. The drug is targeting two significant therapeutic areas – neuroprotection and cardioprotection – with a first-in-class novel mode of action. It is an exciting time for Nyrada ahead of Phase I first in human trials in Australia for its neuroprotection program, expected to commence later this year following the completion of GLP studies. Please select the link to watch the full interview: https://bit.ly/4h1dE1J #biotech #ASX #ausbiz  John Moore

Nyrada Inc. (ASX:NYR) has released a sixth update on its Brain Injury program Good Laboratory Practice (GLP) studies. An in vivo micronucleus study was completed providing further data to support safety of Nyrada’s lead Brain Injury drug candidate NYR-BI03. This study, performed in rats and conducted under GLP conditions, assessed whether NYR-BI03 causes genetic damage. There was no increase in markers of genotoxicity in treated animals compared with control treated animals. Subject to satisfactory completion of all GLP studies, Nyrada will submit a Human Research Ethics Application with the expectation of commencing its first in human Phase I clinical trial in late 2QFY2025 (quarter ending December 2024). More information available at https://bit.ly/3BK5v1d. John Moore James Bonnar

Nyrada Inc. (ASX:NYR) today released an updated investor presentation slide deck. Please click the following link to view. https://bit.ly/3YaMdLw James Bonnar John Moore

Nyrada Inc. (ASX:NYR) today announced that its lead drug candidate demonstrated significant cardioprotection in a preclinical rat study. This is in addition to its already demonstrated efficacy in stroke. In this study, NYR-BI03 offered strong and statistically significant cardioprotection following a myocardial infarction with cardiac tissue damage reduced by 86 percent. NYR-BI03 additionally demonstrated superior efficacy in this study compared to Captopril, an FDA-approved therapy. This result broadens the potential therapeutic applications for NYR-BI03 to include coronary heart disease. The Global market for myocardial infarction therapies is anticipated to reach US$3.7 billion by 2032 offering an additional and significant market opportunity for Nyrada.  Nyrada continues to pioneer Transient Receptor Potential Canonical (TRPC) channel-blocking therapies and NYR-BI03 is first-in-class with a novel mechanism of action. More information available at https://bit.ly/47QujAD. John Moore James Bonnar